articleJournal of the National Comprehensive Cancer NetworkJul 1, 2019BRONZE OA

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

JAJaffer A. AjaniTAThomas A. D’AmicoDJDavid J. BentremJCJoseph ChaoCUCarlos U. Corvera

The University of Texas MD Anderson Cancer Center · Cancer Institute (WIA) · +36 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team…

Citation impact

1,094
total citations
FWCI
140.66
Percentile
100%
References
156
Citations per year

Authors

38

Topics & keywords

Topics
Keywords
  • Medicine
  • Ramucirumab
  • Internal medicine
  • Esophageal cancer
  • Oncology
  • Esophagogastric junction
  • Esophagus
  • Adenocarcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding